Aurealis Therapeutics Raises CHF 8 Million to Complete Phase 2 Clinical Studies in Chronic Wounds and Accelerate Oncology Program
Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, has raised CHF 8 million from existing investors and shareholders. The funds will be primarily used to complete Phase 2 clinical studies with Aurealis lead product AUP-16 for Chronic Wounds, such as Diabetic […]
Aurealis Therapeutics Announces Peer-Reviewed Paper Published from Phase 1 Study of AUP-16 for Non-Healing Diabetic Foot Ulcers
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, is proud to announce the publication of its AUP-16 Phase 1 clinical trial results in the peer-reviewed journal Therapeutic Advances in Endocrinology and Metabolism. The scientific paper, titled “Multi-target gene therapy AUP1602-C to improve healing and quality of […]
Aurealis Therapeutics Announces Last Patient Last Treatment in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, is pleased to announce that the last patient in its DIAMEND AUP-16 Phase 2 clinical trial on Diabetic Foot Ulcers (DFUs) has completed treatment. This important milestone marks the end of the treatment phase and initiates a 12-month […]
Aurealis Therapeutics Proudly Sponsors EWMA Diabetic Foot Committee
Aurealis Therapeutics is pleased to announce our sponsorship of the newly established EWMA Diabetic Foot Committee, an initiative launched by the European Wound Management Association (EWMA) in 2023. This committee is dedicated to improving the management and care of diabetic foot ulcers (DFUs) across Europe by implementing an International Working Group on the Diabetic Foot […]
Aurealis Therapeutics Completes Patient Recruitment in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, announced today the successful completion of patient recruitment in its DIAMEND AUP-16 Phase-2 clinical trial on Diabetic Foot Ulcers (DFUs). This achievement is an important milestone in the evaluation of AUP-16’s potential to address the unmet medical needs […]
Interview with Laurent Décory COO at Aurealis Therapeutics | Career journey, AUP-16 advancements and global partnerships
At Aurealis Therapeutics, our mission is to revolutionize the treatment of chronic wounds, cancer, and inflammatory diseases with our multi-target cell and gene therapy platform. Central to this mission is our incredible team, whose dedication and expertise drive our progress forward. Through the Aurealis Therapeutics Team Interviews, we showcase the scientific advancements at our company […]
Aurealis Therapeutics Enhances Board of Directors Expertise by Appointing Tuomo Pätsi as New Member
Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, is pleased to announce the appointment of Tuomo Pätsi as a new member of its Board of Directors. Mr. Pätsi’s election was confirmed on June 18, 2024 during Aurealis Therapeutics’ Annual General Meeting. Existing Board Directors Silvio Inderbitzin, Jean […]
Aurealis Therapeutics Concludes Successful Partnering Week in China
Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced the successful completion of its partnering visit to China from 13-17 May, 2024. The week-long visit, led by CEO Juha Yrjänheikki and COO Laurent Decory, was aimed at strengthening partnerships and exploring potential investment opportunities in one of […]
Interview with Hanna-Riikka Kärkkäinen Head of Quality and Regulatory Affairs at Aurealis Therapeutics | Professional career, AUP-16 PRIME designation, FDA Advice & more
What was the journey that took Hanna-Riikka Kärkkäinen to her current role as Head of Quality and Regulatory Affairs? What does having the PRIME designation for AUP-16 mean? What was the result of the FDA Advice that Aurealis had with respect of AUP-16? How are the preparations to take AUP-16 to the world moving forward? […]
Half of the Patients Successfully Recruited and Randomized in Aurealis Therapeutics DIAMEND AUP-16 Phase-2 Study
Zug, Switzerland and Kuopio, Finland, March 11, 2024. Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced today the successful recruitment and randomization of half of the patients expected to participate in its DIAMEND AUP-16 Phase-2 clinical trial on Diabetic Foot Ulcers (DFUs). AUP-16 is Aurealis Therapeutics’ […]
